Kensey Nash
This article was originally published in The Gray Sheet
Executive Summary
Proposed secondary offering of 3.2 mil. shares of common stock includes 2.5 mil. shares to be offered by the company and 700,000 shares to be offered by certain selling shareholders. A portion of the proceeds will be used to continue development of the Aegis Vortex atherectomy system to open coronary bypass grafts, conduct clinical trials and complete regulatory submissions for the device (1"The Gray Sheet" Aug. 16, 1999, p. 8). Funds will also be used for debt repayment and general corporate purposes. Prudential Vector Healthcare Group is lead manager of the offering; PaineWebber and Warburg Dillon Read will act as co-managers
You may also be interested in...
Kensey Nash Evaluating Aegis Vortex Atherectomy System In Pilot Study
Kensey Nash's recently initiated pilot study for its Aegis Vortex System (AVS) for treating occluded saphenous vein grafts is designed to support FDA approval for an estimated 300-patient pivotal trial.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.